These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 6404528)

  • 41. Role of natural killer cells in iscador mediated inhibition of metastasis by adoptive immunotherapy.
    Antony S; Kuttan R; Kuttan G
    Immunol Invest; 2000 Aug; 29(3):219-31. PubMed ID: 10933606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunomodulatory effects of iscador: a Viscum album preparation.
    Hajto T
    Oncology; 1986; 43 Suppl 1():51-65. PubMed ID: 2433654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Mistletoe therapy. An alternative cancer treatment].
    Ernst E
    MMW Fortschr Med; 2000 Nov; 142(45):52-3. PubMed ID: 11107826
    [No Abstract]   [Full Text] [Related]  

  • 44. Viscotoxins, mistletoe lectins and their isoforms in mistletoe (Viscum album L.) extracts Iscador.
    Urech K; Schaller G; Jäggy C
    Arzneimittelforschung; 2006 Jun; 56(6A):428-34. PubMed ID: 16927522
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Mistletoe therapy in cancer treatment: pros and cons].
    Wiebelitz KR; Beer AM; Heinrich B
    MMW Fortschr Med; 2009 Nov; 151(46):30-1. PubMed ID: 20043390
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of a preparation from Viscum album on tumor development in vitro and in mice.
    Kuttan G; Vasudevan DM; Kuttan R
    J Ethnopharmacol; 1990 Apr; 29(1):35-41. PubMed ID: 2345458
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The case for mistletoe in the treatment of laryngeal cancer.
    Shakeel M; Trinidade A; Geider S; Ah-See KW
    J Laryngol Otol; 2014 Mar; 128(3):302-6. PubMed ID: 24548675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
    Kleeberg UR; Suciu S; Bröcker EB; Ruiter DJ; Chartier C; Liénard D; Marsden J; Schadendorf D; Eggermont AM;
    Eur J Cancer; 2004 Feb; 40(3):390-402. PubMed ID: 14746858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prevention of recurrence of bronchial carcinomas after surgery by means of the mistletoe extract Iscador. Results of a clinical study from 1969-1971].
    Salzer G; Havelec L
    Onkologie; 1978 Dec; 1(6):264-7. PubMed ID: 366493
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Value of mistletoe therapy in carcinoma patients].
    Rostock M; Unger C
    Internist (Berl); 1998 Dec; 39(12):1294-5. PubMed ID: 10198836
    [No Abstract]   [Full Text] [Related]  

  • 51. [In vitro studies of the effect of a mistletoe preparation on melanoma cells].
    Bantel E; Breuninger H
    Z Hautkr; 1990 Jun; 65(6):562-4, 567. PubMed ID: 2389589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mistletoe lectins: telomerase inhibitors in alternative cancer therapy.
    Li SS
    Drug Discov Today; 2002 Sep; 7(17):896-7. PubMed ID: 12546929
    [No Abstract]   [Full Text] [Related]  

  • 53. Misteltoe (Iscador) therapy in stage IV renal adenocarcinoma. A phase II study in patients with measurable lung metastases.
    Kjaer M
    Acta Oncol; 1989; 28(4):489-94. PubMed ID: 2477047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro.
    Stein G; Berg PA
    Eur J Clin Pharmacol; 1994; 47(1):33-8. PubMed ID: 7988621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mistletoe in immunology and the clinic (short review).
    Stein GM; Schietzel M; Büssing A
    Anticancer Res; 1998; 18(5A):3247-9. PubMed ID: 9858890
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract.
    Bar-Sela G; Goldberg H; Beck D; Amit A; Kuten A
    Anticancer Res; 2006; 26(1B):709-13. PubMed ID: 16739342
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human cancer cells exhibit in vitro individual receptiveness towards different mistletoe extracts.
    Knöpfl-Sidler F; Viviani A; Rist L; Hensel A
    Pharmazie; 2005 Jun; 60(6):448-54. PubMed ID: 15997835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [What prospects of success does Iscador therapy offer in advanced ovarian cancer?].
    Hassauer W; Gutsch J; Burkhardt R
    Onkologie; 1979 Feb; 2(1):28-36. PubMed ID: 392367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Presence of a receptor for the active component of Iscador in ascites fluid of tumour bearing mice.
    Kuttan G; Vasudevan DM; Kuttan R
    Cancer Lett; 1989 Dec; 48(3):223-7. PubMed ID: 2605571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of clinically diagnosed equine sarcoid with a mistletoe extract (Viscum album austriacus).
    Christen-Clottu O; Klocke P; Burger D; Straub R; Gerber V
    J Vet Intern Med; 2010; 24(6):1483-9. PubMed ID: 21039860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.